12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bavituximab: Updated Phase IIb data

Peregrine said investors should not rely on data previously reported from a double-blind, placebo-controlled, international Phase IIb trial evaluating bavituximab plus docetaxel for the second-line treatment of NSCLC. Peregrine said it discovered "major discrepancies between some patient sample test results and patient treatment code assignments" while preparing for an end-of-Phase II meeting with FDA. The company added that the source of...

Read the full 285 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >